XML 47 R33.htm IDEA: XBRL DOCUMENT
v3.23.3

Segment Data (Tables) | 12 Months Ended
--- | ---
Sep. 30, 2023
Segment Reporting [Abstract] |
Revenue from External Customers by Geographic Areas | Financial information for the Company’s segments is detailed below. The Company has no material intersegment revenues.
(Millions of dollars) | 2023 |  | 2022 |  | 2021
| United States |  | International |  | Total |  | United States |  | International |  | Total |  | United States |  | International |  | Total
Medical |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Medication Delivery Solutions | $ | 2,519 |  |  | $ | 1,774 |  |  | $ | 4,293 |  |  | $ | 2,483 |  |  | $ | 1,825 |  |  | $ | 4,308 |  |  | $ | 2,253 |  |  | $ | 1,848 |  |  | $ | 4,101 |
Medication Management Solutions | 2,303 |  |  | 677 |  |  | 2,980 |  |  | 1,935 |  |  | 598 |  |  | 2,533 |  |  | 1,863 |  |  | 570 |  |  | 2,432 |
Pharmaceutical Systems | 666 |  |  | 1,563 |  |  | 2,229 |  |  | 533 |  |  | 1,468 |  |  | 2,001 |  |  | 428 |  |  | 1,400 |  |  | 1,828 |
Total segment revenues | $ | 5,488 |  |  | $ | 4,014 |  |  | $ | 9,502 |  |  | $ | 4,950 |  |  | $ | 3,891 |  |  | $ | 8,841 |  |  | $ | 4,544 |  |  | $ | 3,817 |  |  | $ | 8,361 |
Life Sciences |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Integrated Diagnostic Solutions | $ | 1,774 |  |  | $ | 1,850 |  |  | $ | 3,624 |  |  | $ | 2,190 |  |  | $ | 1,995 |  |  | $ | 4,185 |  |  | $ | 2,477 |  |  | $ | 2,748 |  |  | $ | 5,225 |
Biosciences | 603 |  |  | 906 |  |  | 1,509 |  |  | 542 |  |  | 838 |  |  | 1,379 |  |  | 503 |  |  | 802 |  |  | 1,305 |
Total segment revenues | $ | 2,377 |  |  | $ | 2,756 |  |  | $ | 5,133 |  |  | $ | 2,732 |  |  | $ | 2,833 |  |  | $ | 5,564 |  |  | $ | 2,980 |  |  | $ | 3,550 |  |  | $ | 6,530 |
Interventional |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Surgery | $ | 1,159 |  |  | $ | 338 |  |  | $ | 1,497 |  |  | $ | 1,094 |  |  | $ | 306 |  |  | $ | 1,400 |  |  | $ | 1,023 |  |  | $ | 274 |  |  | $ | 1,296 |
Peripheral Intervention | 1,016 |  |  | 849 |  |  | 1,865 |  |  | 960 |  |  | 799 |  |  | 1,759 |  |  | 931 |  |  | 780 |  |  | 1,711 |
Urology and Critical Care | 1,073 |  |  | 301 |  |  | 1,374 |  |  | 986 |  |  | 319 |  |  | 1,305 |  |  | 894 |  |  | 338 |  |  | 1,232 |
Total segment revenues | $ | 3,247 |  |  | $ | 1,489 |  |  | $ | 4,736 |  |  | $ | 3,040 |  |  | $ | 1,424 |  |  | $ | 4,464 |  |  | $ | 2,847 |  |  | $ | 1,392 |  |  | $ | 4,239 |
Total Company revenues from continuing operations | $ | 11,113 |  |  | $ | 8,258 |  |  | $ | 19,372 |  |  | $ | 10,722 |  |  | $ | 8,148 |  |  | $ | 18,870 |  |  | $ | 10,371 |  |  | $ | 8,760 |  |  | $ | 19,131 |
Financial Information for Company's Segments | The following tables provide a reconciliation of segment operating income to Income from Continuing Operations before Income Taxes and segment information for both capital expenditures and depreciation and amortization.
(Millions of dollars) | 2023 |  | 2022 |  | 2021
Income from Continuing Operations Before Income Taxes |  |  |  |  |
Medical (a) (b) | $ | 1,967 |  |  | $ | 2,215 |  |  | $ | 1,985 |
Life Sciences | 1,585 |  |  | 1,710 |  |  | 2,391 |
Interventional | 1,217 |  |  | 1,081 |  |  | 933 |
Total Segment Operating Income | 4,769 |  |  | 5,006 |  |  | 5,311 |
Acquisition-related integration and restructuring expense | (313) |  |  | (173) |  |  | (179) |
Net interest expense | (403) |  |  | (382) |  |  | (460) |
Other unallocated items (c) | (2,391) |  |  | (2,668) |  |  | (2,981) |
Total Income from Continuing Operations Before Income Taxes | $ | 1,662 |  |  | $ | 1,783 |  |  | $ | 1,692 |
Capital Expenditures |  |  |  |  |
Medical | $ | 563 |  |  | $ | 602 |  |  | $ | 740 |
Life Sciences | 139 |  |  | 213 |  |  | 297 |
Interventional | 138 |  |  | 130 |  |  | 125 |
Corporate and All Other | 35 |  |  | 28 |  |  | 32 |
Total Capital Expenditures | $ | 874 |  |  | $ | 973 |  |  | $ | 1,194 |
Depreciation and Amortization |  |  |  |  |
Medical | $ | 1,199 |  |  | $ | 1,144 |  |  | $ | 1,097 |
Life Sciences | 277 |  |  | 283 |  |  | 352 |
Interventional | 799 |  |  | 789 |  |  | 769 |
Corporate and All Other | 13 |  |  | 13 |  |  | 12 |
Total Depreciation and Amortization | $ | 2,288 |  |  | $ | 2,229 |  |  | $ | 2,230 |
(a)The amounts in 2023, 2022 and 2021 include charges of $653 million, $72 million and $56 million, respectively, recorded to Cost of products sold, to adjust estimated future product remediation costs. (b)The amount in 2022 includes a charge of $54 million, recorded to Cost of products sold, to write down the carrying value of certain fixed assets in the Pharmaceutical Systems unit. (c)Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense. The amount in 2023 includes a pre-tax gain recognized on the Company's sale of its Surgical Instrumentation platform of approximately $268 million, which is further discussed in Note 2. The amount in 2021 includes a pre-tax charge recorded to Other operating (income) expense, net, related to certain product liability matters of $361 million, as further discussed in Note 6.
Revenues to Unaffiliated Customers and Long-lived Assets Including Property, Plant and Equipment | The table below shows revenues from continuing operations and long-lived assets of continuing operations by geographic area:
(Millions of dollars) | 2023 |  | 2022 |  | 2021
Revenues |  |  |  |  |
United States | $ | 11,113 |  |  | $ | 10,722 |  |  | $ | 10,371 |
EMEA | 4,244 |  |  | 4,043 |  |  | 4,548 |
Greater Asia | 2,913 |  |  | 3,047 |  |  | 3,069 |
Other | 1,102 |  |  | 1,058 |  |  | 1,142 |
| $ | 19,372 |  |  | $ | 18,870 |  |  | $ | 19,131 |
Long-Lived Assets |  |  |  |  |
United States | $ | 35,732 |  |  | $ | 36,617 |  |  | $ | 35,896 |
EMEA | 5,317 |  |  | 5,126 |  |  | 5,778 |
Greater Asia | 1,521 |  |  | 1,528 |  |  | 1,607 |
Other | 1,116 |  |  | 1,079 |  |  | 860 |
Corporate | 418 |  |  | 442 |  |  | 465 |
| $ | 44,104 |  |  | $ | 44,792 |  |  | $ | 44,606 |

X
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph a -SubTopic 10 -Topic 280 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration